Европска Унија - Мелтешки - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - neoplasmi prostatiċi - terapija endokrinali - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - xospata huwa indikat bħala monoterapija għall-kura ta ' pazjenti adulti li rkadew jew refrattorji lewkimja majelojde akuta (aml) b'flt3 mutazzjoni.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - aġenti antineoplastiċi - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - budesonide / formoterol teva huwa indikat fl-adulti ta '18-il sena' l fuq biss. asthmabudesonide/formoterol teva huwa indikat fit-trattament regolari ta ' l-ażżma, fejn l-użu tal-kombinazzjoni (kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonist) huwa xieraq:f'pazjenti li mhumiex adegwatament ikkontrollati bil-kortikosterojdi meħuda man-nifs u l - "kif meħtieġ" man-nifs qasir waqt li jaġixxi β2 adrenoceptor agonisti. fjorin pazjenti li diġà ikkontrollati adegwatament fuq iż-żewġ kortikosterojdi meħuda man-nifs u li jaħdem fit-tul β2 adrenoceptor agonisti. copdsymptomatic-trattament ta ' pazjenti b'indeboliment serju copd (fev1 < 50% mbassra-normal) u l-istorja tal-aggravar tal-attakki ripetuti, li għandhom sinifikanti sintomi minkejja regolari it-terapija b'taġixxi fit-tul bronkodilataturi.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - budesonide / formoterol teva pharma b. hija indikata fl-adulti ta '18-il sena u akbar biss. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - sleep inizjattiva u maintenance disorders - psikolettiċi - circadin huwa indikat bħala monoterapija għat-trattament għal żmien qasir ta 'nuqqas ta' rqad primarju kkaratterizzat minn kwalità fqira ta 'rqad f'pazjenti li għandhom 55 sena jew aktar.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - antiġeni tal-herpesvirus tal-klieb (strain f205) - immunoloġiċi għall-canidae - klieb - immunizzazzjoni attiva ta 'klieb nisa biex jipprevjenu l-mortalità, sinjali kliniċi u leżjonijiet fi ġriewi li jirriżultaw minn infezzjonijiet tal-virus tal-herpes tal-klieb akkwistati fl-ewwel ftit jiem tal-ħajja.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp1338 virus - immunostimulanti, antineoplastika u immunomodulanti l-aĠenti, immunostimulanti, - qtates - immunoterapija li jintuża flimkien mal-kirurġija u r-radjuterapija fi qtates b'fibrosarcoma (2 sa 5 ċm dijametru) mingħajr metastasi jew tal-lymph node-involviment, biex jitnaqqas ir-riskju ta'rikaduta u jżidu l-żmien għar-rikaduta (lokali rikorrenza jew metastasi).

Европска Унија - Мелтешки - EMA (European Medicines Agency)

merial - parvovirus tal-papri muscovy ħaj attenwat - immunoloġiċi għall-aves, papri parvovirus, vaċċini virali Ħajjin - papri - immunizzazzjoni attiva ta 'papri biex jipprevjenu l-mortalità1 u biex tnaqqas it-telf ta' piż u l-leżjonijiet tal-parvovirosis tal-papri u l-marda ta 'derzsy. 1fl-assenza ta 'antikorpi derivati ​​mill-omm.